Improving genetic diagnostic yield in a large cohort of children with rare vascular anomalies or PIK3CA-related overgrowth spectrum
Genetics in Medicine Open · 2024 · 2 · 100837
DOI: 10.1016/j.gimo.2023.100837 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetics in Medicine Open, 2024. Verfasst von Timothy E Green und 12 weiteren Autor:innen. Beteiligte Einrichtung: Epilepsy Research Centre, Department of Medicine (Austin Hospital), University of Melbourne, Heidelberg, Australia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Purpose
Drugs that attenuate hyperactivation of the phosphatidylinositol 3-kinase-Akt and Ras-mitogen-activated protein kinase signaling pathways are emerging treatments for children with rare, intractable vascular anomalies or PIK3CA-related overgrowth spectrum (PROS) with an eligible genetic diagnosis. However, access to genetic testing remains a barrier to genetic diagnosis. Here, we implement a targeted molecular diagnostic strategy for vascular anomalies or PROS.
Methods
We applied a novel genetic testing strategy to children with vascular anomalies or PROS using a tiered approach of (1) droplet digital PCR, (2) Sanger sequencing, (3) high-depth exome sequencing, and (4) reanalysis of existing clinical exome data.
Results
We applied this strategy to 60 individuals detecting pathogenic somatic variants in 33 of 60 (55%). This included 26 individuals with slow-flow lesions with variants in PIK3CA, TEK, GNAQ, GNA11, BRAF, or PIK3R1, 4 individuals with fast-flow lesions with variants in KRAS or MAP2K1, 1 individual with a PIK3CA variant and a mixed phenotype, and 2 individuals with PIK3CA variants and PROS without vascular anomalies.
Conclusion
We demonstrate an effective genetic diagnostic strategy for children with vascular anomalies or PROS identifying somatic variants in 55% of individuals. Increasing genetic diagnostic yield extends the clinicogenetic spectrum and may provide access for those with intractable disease to therapeutic drug trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Epilepsy Research Centre, Department of Medicine (Austin Hospital), University of Melbourne, Heidelberg, Australia.
- Victorian Clinical Genetics Services, Melbourne, Parkville, Australia.
- Tasmanian Clinical Genetics Service, Hobart, Tasmania, Australia.
- Murdoch Children's Research Institute, Melbourne, Parkville, Australia.
- Royal Children's Hospital Department of Paediatrics, University of Melbourne, Parkville, Australia.
- Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
Zitieren
APA
Green, T. E., Garza, D., Brown, N. J., de Silva, M. G., Bennett, M. F., Tubb, C., Phillips, R. J., MacGregor, D., Robertson, S. J., Bekhor, P., Simpson, J., Penington, A. J., & Hildebrand, M. S. (2024). Improving genetic diagnostic yield in a large cohort of children with rare vascular anomalies or PIK3CA-related overgrowth spectrum. Genetics in Medicine Open, 2, 100837. https://doi.org/10.1016/j.gimo.2023.100837
Vancouver
Green TE, Garza D, Brown NJ, de Silva MG, Bennett MF, Tubb C, et al. Improving genetic diagnostic yield in a large cohort of children with rare vascular anomalies or PIK3CA-related overgrowth spectrum. Genetics in Medicine Open. 2024;2:100837. doi:10.1016/j.gimo.2023.100837
BibTeX
@article{Green2024,
author = {Green, Timothy E and Garza, Denisse and Brown, Natasha J and de Silva, Michelle G and Bennett, Mark F and Tubb, Caitlin and Phillips, Roderic J and MacGregor, Duncan and Robertson, Susan J and Bekhor, Phillip and Simpson, Jodie and Penington, Anthony J and Hildebrand, Michael S},
title = {Improving genetic diagnostic yield in a large cohort of children with rare vascular anomalies or PIK3CA-related overgrowth spectrum},
journal = {Genetics in Medicine Open},
year = {2024},
volume = {2},
pages = {100837},
doi = {10.1016/j.gimo.2023.100837}
}
EUVIMED